Issuer Client News

News & Events

Dario Presents New Research at ISPOR Europe 2026 Validating a Biometric-Driven Approach to Estimating Healthcare Cost Savings and ROI - Consistent with Published Benchmarks and Without Waiting for Claims Data

Dario Presents New Research at ISPOR Europe 2026 Validating a Biometric-Driven Approach to Estimating Healthcare Cost Savings and ROI - Consistent with Published Benchmarks and Without Waiting for Claims Data

New methodology addresses critical market need for a transparent, replicable model to estimate healthcare cost savings and ROI when medical claims data are unavailable or delayed

Further demonstrates Dario's economic value in support of new contract wins, contract renewals and expansion of existing customer relationships

NEW YORK, Nov. 16, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the presentation of new research at ISPOR Europe 2026, a leading international conference focused on health economics and outcomes research, held November 8–11 in Vienna, Austria. The research highlights Dario's methodology for estimating healthcare cost savings and return on investment ("ROI") based on biometric improvements achieved by members participating in digital chronic disease management programs.

DarioHealth Corp. Logo

The presentation, titled "Estimating Individual-Level Medical Cost Savings from Digital Chronic Disease Management: A Biometric-to-PMPM Proxy Methodology," was delivered by Yifat Hershcovitz, Ph.D., Vice President of Clinical and Scientific Affairs at DarioHealth. The research describes a retrospective model that translates observed changes in blood pressure, blood glucose and weight into projected reductions in healthcare expenditures using published medical cost data.

Dario's model addresses the need among health plans, employers and enterprise healthcare purchasers to link measurable clinical outcomes to estimated cost savings. Leveraging the model, Dario is able to provide customers with evidence of program value in support of purchasing decisions, contract renewals and expansion into additional conditions and populations – without waiting for medical claims data, which often take months to become available or may not be accessible.

"This is a powerful study that provides an evidence-based and replicable method to demonstrate the in-year cost savings that Dario delivers specific to cardiometabolic disease. Moreover, it quantifies how savings are amplified when multiple conditions are enrolled," said Erez Raphael, Chief Executive Officer of DarioHealth. "This research gives Dario clients a validated process to confirm that their investment in Dario for cardiometabolic health is delivering the cost savings they contracted for – without the added administrative costs, time or reliance on claims analysis when claims data are delayed or not available."

"One of the biggest challenges in demonstrating the economic value of digital health is the limited availability of timely medical claims data," said Yifat Hershcovitz, Ph.D., Vice President of Clinical and Scientific Affairs at DarioHealth. "Our methodology bridges that gap directly by translating observed changes in clinical measures into transparent, evidence-based estimates of potential healthcare savings. This gives healthcare purchasers a practical way to evaluate program performance and understand its potential financial impact."

About DarioHealth Corp.

DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.

Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the potential benefits, applicability and reliability of its biometric-driven methodology for estimating healthcare cost savings and return on investment; the ability of the methodology to estimate potential healthcare cost savings without medical claims data; the potential economic value of the Company's digital chronic disease management programs, including the potential for increased savings associated with managing multiple conditions; and the potential use of the methodology to support customer purchasing decisions, new customer relationships, contract renewals and the expansion of existing customer relationships. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com 
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dario-presents-new-research-at-ispor-europe-2026-validating-a-biometric-driven-approach-to-estimating-healthcare-cost-savings-and-roi--consistent-with-published-benchmarks-and-without-waiting-for-claims-data-302939190.html

SOURCE DarioHealth Corp.

Brokerage and investment advisory products and services, are offered through Aegis Capital Corp, a member of FINRA and SIPC. Insurance products are made available through, ACC General Agency, a licensed insurance agency. For those persons inquiring from states where a specific associate is not currently securities and/or insurance licensed, the associate will not transact business in that state or provide follow-up individual responses, until after the associate obtains the appropriate registration in the applicable state.

The information provided should not be relied upon in isolation for the purpose of making an investment decision. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. Prior to making any investment or financial decision, an investor should seek advice from a financial, legal, tax and other professional that consider all of the particular facts and circumstances of an investor's situation. The opinions expressed and material provided are for information purposes only and is not an offer, recommendation, or solicitation of any product, strategy or transaction. Any views, strategies or products discussed may not be appropriate or suitable for all individuals and are subject to risks.

Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

Check the background of your financial professional on FINRA's BrokerCheck

Form CRS and General Disclosures

Aegis Risk Disclosures